⌘K

Login Start Free

Home/Filings/4/0000950170-25-003015

4//SEC Filing

Lebwohl David 4

Accession 0000950170-25-003015

CIK 0001652130other

View on SEC.gov Company Profile

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 5:20 PM ET

Size

4.8 KB

Accession

0000950170-25-003015

Insider Transaction Report

Form 4

Period: 2025-01-03

Intellia Therapeutics, Inc.NTLA

EVP, Chief Medical Officer

Transactions

Sale
Common Stock
2025-01-03$12.18/sh−9,557$116,404→ 87,666 total

Footnotes (1)

[F1]Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

Entity typeother

Related Parties

1

filerCIK 0001810882

Filing Metadata

Form type: 4
Filed: Jan 6, 7:00 PM ET
Accepted: Jan 7, 5:20 PM ET
Size: 4.8 KB

View on SEC.gov